Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breast Implant Patient Preferences Topic Of New FDA Study

Executive Summary

The US agency’s study will look at how the potential cancer risk tied to textured breast implants, as well as other factors, play into how patients decide what type of implants to get.

You may also be interested in...



New Cancer Risks Linked To Breast Implants, FDA Warns

The US FDA has learned of new cancer risks associated with breast implants that differ from cancers the agency has warned about in the past.

FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened

The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.

Joint Mission: FDA And VA Partner On Device Development Initiative

The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel